Here’s Otsuka’s digital health strategy around mental health
Otsuka's top U.S.-based leaders spoke about the company's partnerships in mental health and how it is driving innovation in big pharma.
Alkermes gets FDA approval for monthly schizophrenia drug
Schizophrenia medication treatment could become easier and more effective with Alkermes' FDA approval for Aristada.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
#JPM15: Bristol-Myers Squibb bullish on immuno-oncology, but what of the patent expiries?
Despite the influx of recent, positive news from Bristol-Myers Squibb, CEO Lamberto Andreotti remained a bit cagey during today’s JP Morgan presentation about the company’s plan this year to recover from major drugs like Abilify and Baraclude going off-patent. The past three weeks alone have been quite bullish for the pharma giant: With the “earlier-than-expected” approval of Opdivo for […]